Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals recently granted inducement stock options to five new employees, totaling 18,000 shares at an exercise price of $16.83 per share, aligning with the company's stock price on the grant date of September 1, 2022. The options will vest over four years, starting with one-fourth on the anniversary of the commencement date. This initiative adheres to Nasdaq Listing Rule 5635(c)(4), reflecting KalVista's focus on growth and talent acquisition in the pharmaceutical sector.

KalVista Pharmaceuticals (KALV) announced the initiation of its KONFIDENT-S open-label extension study, providing an additional two years of treatment with sebetralstat for hereditary angioedema (HAE) patients. This trial is designed to assess long-term safety and efficacy, with a subtrial including adolescents aged 12-17. Data collected will support a planned FDA NDA filing in 2024, following the ongoing Phase 3 KONFIDENT trial expected to conclude in late 2023. The company aims to position sebetralstat as the first oral, on-demand treatment for HAE.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement stock options to a newly hired employee on August 1, 2022. The compensation committee granted options to purchase 7,000 shares at an exercise price of $12.21 per share, equal to the closing price on the grant date. The options vest one-fourth on the one-year anniversary and the remainder monthly over three years, contingent on continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 1st Annual H.C. Wainwright Hereditary Angioedema Conference, set for July 20, 2022, at 12:00 p.m. ET. CEO Andrew Crockett will engage in an expert panel on oral treatments for hereditary angioedema (HAE) at 11:00 a.m. ET. Webcasts of the presentation and panel will be available on the company's website, with an audio archive accessible for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for HAE and diabetic macular edema.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) reported on its clinical trials and financial performance for the fiscal year ending April 30, 2022. Key updates include ongoing enrollment in the KONFIDENT Phase 3 trial for sebetralstat and KVD824's KOMPLETE Phase 2 trial. The company received EU Orphan Drug status for sebetralstat, promising 10 years of market exclusivity. Financially, KalVista recorded a net loss of $82.3 million for the fiscal year, up from $46.2 million the previous year, largely due to increased R&D costs. The cash position stood at $166.2 million.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement stock options to two newly-hired employees, totaling 8,000 shares with an exercise price of $9.90 per share. This price corresponds to the stock's closing price on July 1, 2022. The options vest over four years, beginning with a one-year cliff, and have a 10-year term.

KalVista focuses on developing oral protease inhibitors for unmet medical needs, targeting conditions like hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals (NASDAQ: KALV) presented promising data on its oral plasma kallikrein inhibitor, sebetralstat, and oral Factor XIIa inhibitor at the EAACI2022 conference in Prague. Sebetralstat demonstrated effective relief in 80% of acute attacks within 12 hours, unaffected by meal timing. Preclinical results for KV998086 showed potential for once-daily prophylaxis against hereditary angioedema (HAE). The population pharmacokinetic study broadens treatment possibilities for adolescents without dose adjustments, enhancing the company’s positioning for future trials.

KalVista Pharmaceuticals (NASDAQ: KALV) has announced the acceptance of multiple abstracts for presentation at the 2022 EAACI Congress in Prague, taking place from July 1-3, 2022. Key presentations include:

• Identification of potent oral Factor XIIa inhibitors by Allen C. Clermont, discussing angioedema.
• Efficacy of Sebetralstat in a Phase 2 clinical trial by Emel Aygören-Pürsün.
• Efficacy and Safety of Sebetralstat in a Phase 3 study by Andrea Zanichelli.
• Population Pharmacokinetic Analysis of KVD900 by Sinisa Savic.

KalVista focuses on oral protease inhibitors for diseases like hereditary angioedema and diabetic macular edema.

KalVista Pharmaceuticals (NASDAQ: KALV) showcased significant advancements at the KININ2022 conference, presenting promising preclinical data on oral Factor XIIa inhibitors, which block the kallikrein kinin system (KKS) in disease models. CEO Andrew Crockett highlighted these inhibitors as potential treatments for hereditary angioedema (HAE). KalVista also shared data on sebetralstat, an oral therapy for acute HAE attacks, currently in Phase 3 KONFIDENT trial. The company aims to improve patient outcomes in KKS-related diseases with its innovative therapies.